# GPR52

## Overview
GPR52 is a gene that encodes the G protein-coupled receptor 52, a member of the G protein-coupled receptor (GPCR) family, which is characterized by its seven-transmembrane domain structure. This receptor is predominantly expressed in the striatum, a critical brain region involved in motor control and cognitive functions. As a Gs-coupled receptor, GPR52 plays a significant role in modulating intracellular signaling pathways by stimulating the production of cyclic adenosine monophosphate (cAMP), a key second messenger. The receptor's involvement in neurotransmitter systems, particularly dopamine signaling, underscores its importance in maintaining neuronal circuit balance, which is crucial for mood, cognition, and motor control. GPR52's regulatory role in huntingtin protein levels further highlights its potential impact on neurodegenerative diseases such as Huntington's disease (Krieg2023GPR52; Komatsu2014Anatomical; Yao2015A).

## Function
GPR52 is a G protein-coupled receptor (GPCR) predominantly expressed in the striatum, a region of the brain involved in motor control and cognitive functions. It is a Gs-coupled receptor, meaning it activates the Gs protein, which in turn stimulates the production of cyclic adenosine monophosphate (cAMP), a crucial second messenger in cellular signaling pathways (Krieg2023GPR52; Komatsu2014Anatomical). 

In healthy human cells, GPR52 is involved in modulating neurotransmitter systems, particularly dopamine signaling. It is co-expressed with dopamine D2 receptors in medium spiny neurons of the striatum, suggesting a role in counteracting D2 receptor signaling and potentially enhancing D1 receptor function in the frontal cortex (Wang2020Discovery; Komatsu2014Anatomical). This modulation of dopaminergic transmission is crucial for maintaining balance in neuronal circuits related to mood, cognition, and motor control (Komatsu2014Anatomical).

GPR52 also plays a role in regulating huntingtin (Htt) levels, which is significant for cellular health and function. It stabilizes Htt through cAMP-dependent but protein kinase A (PKA)-independent mechanisms, potentially involving guanine exchange factors (GEFs) and small GTPases (Yao2015A). This activity may contribute to the selective vulnerability of striatal neurons, highlighting GPR52's importance in neurodegenerative conditions like Huntington's disease (Yao2015A).

## Clinical Significance
GPR52 is implicated in several neurological and psychiatric disorders, primarily due to its role in modulating dopaminergic and serotonergic pathways. Alterations in GPR52 expression or function have been associated with Huntington's disease (HD). Studies have shown that targeting GPR52 can lower mutant huntingtin (mHTT) levels and ameliorate HD-related phenotypes. Compounds like E7 and Comp-43, which inhibit GPR52, have been demonstrated to reduce mHTT levels and improve motor function and neuronal survival in HD models (Wang2020GPR52; Song2018Targeting).

GPR52 is also linked to psychiatric disorders such as schizophrenia. It is expressed predominantly in the brain's striatum and overlaps with D1 and D2 dopamine receptors, suggesting its involvement in dopaminergic transmission. This association indicates a potential role in the manifestation of schizophrenia, where D1 receptor activity is reduced, and D2 receptor signaling is overactivated (Komatsu2014Anatomical).

Additionally, GPR52's involvement in emotional behaviors and its co-expression with dopamine receptors suggest a role in mood disorders, including anxiety and anhedonia. Stress hormones can modulate GPR52 levels, further implicating it in stress-related conditions (Watkins2020Orphan).

## Interactions
GPR52, a G protein-coupled receptor, is involved in various signaling pathways, primarily through its interactions with G proteins. It couples with Gs/olf proteins to activate adenylyl cyclase, leading to increased cAMP production, which modulates signaling pathways in the brain. This activity is particularly significant in the striatum, where GPR52 is coexpressed with dopamine D2 receptors in medium spiny neurons, suggesting a role in modulating dopamine signaling (Wang2020Discovery).

The receptor's interactions are not limited to G proteins. GPR52 has been shown to interact with specific ligands, such as the antagonist E7, which acts as an intracellular covalent ligand. E7 targets cysteine residues, particularly C156, disrupting G protein interaction and leading to antagonist behavior. This interaction is unique to GPR52, as C156 is a receptor-selective residue not found in other class A GPCRs (Ma2020Targeted).

GPR52's role in Huntington's disease has been explored through its interaction with antagonists like Comp-43, which reduces mutant huntingtin levels and ameliorates disease-related phenotypes. This suggests that GPR52 may be part of pathways regulating huntingtin levels and neuronal survival (Wang2020GPR52).


## References


[1. (Watkins2020Orphan) Lyndsay R. Watkins and Cesare Orlandi. Orphan g protein coupled receptors in affective disorders. Genes, 11(6):694, June 2020. URL: http://dx.doi.org/10.3390/genes11060694, doi:10.3390/genes11060694. This article has 44 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/genes11060694)

[2. (Song2018Targeting) Haikun Song, Hexuan Li, Shimeng Guo, Yuyin Pan, Yuhua Fu, Zijian Zhou, Zhaoyang Li, Xue Wen, Xiaoli Sun, Bingqing He, Haifeng Gu, Quan Zhao, Cen Wang, Ping An, Shouqing Luo, Youhong Hu, Xin Xie, and Boxun Lu. Targeting gpr52 lowers mutant htt levels and rescues huntington’s disease-associated phenotypes. Brain, 141(6):1782–1798, March 2018. URL: http://dx.doi.org/10.1093/brain/awy081, doi:10.1093/brain/awy081. This article has 37 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1093/brain/awy081)

[3. (Yao2015A) Yuwei Yao, Xiaotian Cui, Ismael Al-Ramahi, Xiaoli Sun, Bo Li, Jiapeng Hou, Marian Difiglia, James Palacino, Zhi-Ying Wu, Lixiang Ma, Juan Botas, and Boxun Lu. A striatal-enriched intronic gpcr modulates huntingtin levels and toxicity. eLife, March 2015. URL: http://dx.doi.org/10.7554/elife.05449, doi:10.7554/elife.05449. This article has 63 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.7554/elife.05449)

[4. (Krieg2023GPR52) Paula F. Krieg, Jana K. Sonner, Roberta Kurelic, Jan Broder Engler, Marlena F. Scharenberg, Simone Bauer, Viacheslav O. Nikolaev, and Manuel A. Friese. Gpr52 regulates camp in t cells but is dispensable for encephalitogenic responses. Frontiers in Immunology, January 2023. URL: http://dx.doi.org/10.3389/fimmu.2022.1113348, doi:10.3389/fimmu.2022.1113348. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2022.1113348)

[5. (Komatsu2014Anatomical) Hidetoshi Komatsu, Minoru Maruyama, Shuuhei Yao, Tokuyuki Shinohara, Kensuke Sakuma, Sachiko Imaichi, Tomoko Chikatsu, Kanako Kuniyeda, Foo Kok Siu, Lam Sock Peng, Katherine Zhuo, Lay Sock Mun, Tan Min Han, Yoshio Matsumoto, Tadatoshi Hashimoto, Nobuyuki Miyajima, Yasuaki Itoh, Kazuhiro Ogi, Yugo Habata, and Masaaki Mori. Anatomical transcriptome of g protein-coupled receptors leads to the identification of a novel therapeutic candidate gpr52 for psychiatric disorders. PLoS ONE, 9(2):e90134, February 2014. URL: http://dx.doi.org/10.1371/journal.pone.0090134, doi:10.1371/journal.pone.0090134. This article has 61 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0090134)

[6. (Wang2020Discovery) Pingyuan Wang, Daniel E. Felsing, Haiying Chen, Sonja J. Stutz, Ryan E. Murphy, Kathryn A. Cunningham, John A. Allen, and Jia Zhou. Discovery of potent and brain-penetrant gpr52 agonist that suppresses psychostimulant behavior. Journal of Medicinal Chemistry, 63(22):13951–13972, November 2020. URL: http://dx.doi.org/10.1021/acs.jmedchem.0c01498, doi:10.1021/acs.jmedchem.0c01498. This article has 14 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1021/acs.jmedchem.0c01498)

[7. (Ma2020Targeted) Mengna Ma, Shimeng Guo, Xi Lin, Shanshan Li, Yiran Wu, Yanping Zeng, Youhong Hu, Suwen Zhao, Fei Xu, Xin Xie, and Wenqing Shui. Targeted proteomics combined with affinity mass spectrometry analysis reveals antagonist e7 acts as an intracellular covalent ligand of orphan receptor gpr52. ACS Chemical Biology, 15(12):3275–3284, December 2020. URL: http://dx.doi.org/10.1021/acschembio.0c00867, doi:10.1021/acschembio.0c00867. This article has 9 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1021/acschembio.0c00867)

[8. (Wang2020GPR52) Congcong Wang, Yu-Fang Zhang, Shimeng Guo, Quan Zhao, Yanping Zeng, Zhicheng Xie, Xin Xie, Boxun Lu, and Youhong Hu. Gpr52 antagonist reduces huntingtin levels and ameliorates huntington’s disease-related phenotypes. Journal of Medicinal Chemistry, 64(2):941–957, November 2020. URL: http://dx.doi.org/10.1021/acs.jmedchem.0c01133, doi:10.1021/acs.jmedchem.0c01133. This article has 11 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1021/acs.jmedchem.0c01133)